Literature DB >> 16832587

Pituitary apoplexy after leuprolide.

Anu Davis1, Shefali Goel, Michalis Picolos, Min Wang, Victor Lavis.   

Abstract

Clinically unsuspected pituitary adenomas are common among adults on autopsy and MRI survey. Acute pituitary hemorrhage is far more rare. We report a case of a 61-year-old male patient with locally advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide. He developed headache and neck pain within a few hours of treatment followed by nausea, vomiting, ptosis and diplopia. Pituitary apoplexy is a potentially life threatening medical emergency. Although the pathophysiology is poorly defined, various conditions and treatments have been reported to trigger apoplexy. Apoplexy has been reported in response to pituitary stimulation by GnRH or GnRH-agonists. Initial stimulatory effects of gonadotropin releasing hormone (GnRH) analogue may induce apoplexy in patients with asymptomatic gonadotroph adenomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832587     DOI: 10.1007/s11102-006-8616-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  13 in total

1.  Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness.

Authors:  H J Eaton; P J Phillips; A Hanieh; J Cooper; J Bolt; D J Torpy
Journal:  Intern Med J       Date:  2001-07       Impact factor: 2.048

2.  Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma.

Authors:  P Chanson; G Schaison
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

3.  Pituitary apoplexy after goserelin.

Authors:  S Ando; T Hoshino; S Mihara
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

Review 4.  Pituitary apoplexy: a review.

Authors:  E R Cardoso; E W Peterson
Journal:  Neurosurgery       Date:  1984-03       Impact factor: 4.654

5.  Precipitating factors in pituitary apoplexy.

Authors:  V Biousse; N J Newman; N M Oyesiku
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

6.  Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.

Authors:  Y Reznik; F Chapon; N Lahlou; N Deboucher; J Mahoudeau
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

Review 7.  Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Authors:  I M Thompson; E J Zeidman; F R Rodriguez
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

8.  Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.

Authors:  A Morsi; S Jamal; J D Silverberg
Journal:  Clin Endocrinol (Oxf)       Date:  1996-01       Impact factor: 3.478

9.  Incidental pituitary lesions in 1,000 unselected autopsy specimens.

Authors:  A Teramoto; K Hirakawa; N Sanno; Y Osamura
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

10.  Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas.

Authors:  B W Chong; W Kucharczyk; W Singer; S George
Journal:  AJNR Am J Neuroradiol       Date:  1994-04       Impact factor: 3.825

View more
  8 in total

1.  Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.

Authors:  Georges Tanios; Nicolas Andrews Mungo; Aaysha Kapila; Kailash Bajaj
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis.

Authors:  Rahel Sahli; Emanuel Christ; Dominique Kuhlen; Olivier Giger; Istvan Vajtai
Journal:  Pituitary       Date:  2009-09-17       Impact factor: 4.107

Review 3.  Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.

Authors:  Yannis Guerra; Evelyn Lacuesta; Francisco Marquez; P B Raksin; Manuel Utset; Leon Fogelfeld
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

4.  The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.

Authors:  Angela Babbo; George T Kalapurakal; Benjamin Liu; Sanija Bajramovic; James P Chandler; John Garnett; John A Kalapurakal
Journal:  Int Urol Nephrol       Date:  2014-04-06       Impact factor: 2.370

Review 5.  GnRH agonist-associated pituitary apoplexy: a case series and review of the literature.

Authors:  Francisco J Guarda; Xiaoling Yu; Philip J Saylor; Lisa B Nachtigall; Naila Shiraliyeva; Melanie S Haines; Michael Bradbury
Journal:  Pituitary       Date:  2021-04-09       Impact factor: 4.107

6.  Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment.

Authors:  Mariana Barbosa; Sílvia Paredes; Maria João Machado; Rui Almeida; Olinda Marques
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-04

7.  Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.

Authors:  Tsung-Yi Huang; Jih-Pin Lin; Ann-Shung Lieu; Yi-Ting Chen; Hung-Sheng Chen; Mei-Yu Jang; Jung-Tsung Shen; Wen-Jeng Wu; Shu-Pin Huang; Yung-Shun Juan
Journal:  World J Surg Oncol       Date:  2013-10-02       Impact factor: 2.754

8.  Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.

Authors:  Rishi Raj; Ghada Elshimy; Aasems Jacob; P V Akhila Arya; Dileep C Unnikrishnan; Riccardo Correa; Zin W Myint
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-22       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.